PTC Therapeutics (PTCT) said Monday that it signed an exclusive global license and collaboration agreement for its PTC518 Huntington's disease program with a subsidiary of Novartis (NVS), and will receive a $1 billion upfront payment.
The company said it will also be entitled to additional payments of up to $1.9 billion based on development, regulatory and sales milestones, plus a profit share in the US and double-digit tiered royalties on international sales.
As part for the deal, PTC Therapeutics said Novartis will be in charge of PTC518's development, manufacturing and commercialization after the completion of the ongoing placebo-controlled portion of a phase 2 trial on PTC518, which is expected in the first half of 2025.
The transaction is expected to close in Q1 2025, said PTC Therapeutics.
PTC Therapeutics shares were up over 20% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。